[Clinical significance of cytokine and cytokine receptor analysis in collagen diseases].
Tanaka
Yoshiya
Y
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015415:Biomarkers / Q000032:analysis; D003095:Collagen Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D016207:Cytokines / Q000032:analysis*; D015195:Drug Design; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D018836:Inflammation Mediators / Q000032:analysis*; D000069285:Infliximab; D020239:Receptor Cross-Talk; D018121:Receptors, Cytokine / Q000032:analysis*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015415:Biomarkers; D016207:Cytokines; D007074:Immunoglobulin G; D018836:Inflammation Mediators; D018121:Receptors, Cytokine; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept